EADV 2026 Recap: Top 5 Psoriasis Headlines

Psoriasis was among the most active areas of discussion at the 2026 European Academy of Dermatology and Venereology (EADV) Congress, held September 30 to October 3 in Vienna, Austria. New head-to-head oral therapy data, long-term results in high-impact disease sites, and expert perspectives on treatment selection were central to the HCPLive team’s coverage.

The following recap highlights 5 notable psoriasis stories from HCPLive’s EADV 2026 coverage:

How Are Oral Therapies Reshaping Psoriasis Treatment?

EADV 2026: Zasocitinib Tops Deucravacitinib for PASI 100 in Plaque Psoriasis

Full results from the phase 3 LATITUDE Atlas trial, an intraclass head-to-head study of 2 tyrosine kinase 2 (TYK2) inhibitors, were presented by Takeda. At Week 16, 36.5% of patients receiving zasocitinib 30 mg once daily achieved PASI 100, compared with 13.9% of those receiving deucravacitinib 6 mg once daily (P < .001). Zasocitinib also outperformed deucravacitinib on PASI 90 (62.5% vs 34.0%) and sPGA 0 (43.2% vs 18.5%). The FDA accepted Takeda’s new drug application for zasocitinib under priority review in September 2026.

Why Zasocitinib Outperformed Deucravacitinib in New Plaque Psoriasis Data

In an interview with HCPLive, LATITUDE Atlas principal investigator Linda Stein Gold, MD, of Henry Ford Health, attributed the difference to zasocitinib’s greater selectivity for TYK2 over other Janus kinases and its longer blockade of IL-23 signaling. She noted differences in complete clearance emerged as early as Week 8. Stein Gold also recommended counseling patients about acne before starting treatment, as it occurred more often with zasocitinib but was typically mild to moderate.

What New Data Emerged in High-Impact Psoriasis?

ICONIC-TOTAL: Icotrokinra Sustains High-Impact Site Clearance at 2 Years

Late-breaking 2-year data from the phase 3 ICONIC-TOTAL trial showed the oral IL-23 receptor antagonist icotrokinra sustained responses at scalp, genital, and hand and foot sites through Week 112. Among 311 randomized patients, clear or almost clear skin was achieved by 74% at the scalp, 89% at the genitals, and 68% at the hands and feet at Week 112. Nail severity improved by a mean of 71%, and exposure-adjusted adverse event rates did not increase over time.

From Injectable to Oral: Optimal Durable Clearance Across the IL-23 Class

Stein Gold and Andrew Blauvelt, MD, MBA, chair of the National Psoriasis Foundation Medical Board, discussed the ICONIC-TOTAL findings in a video interview. Blauvelt noted responses followed plaque thickness, with genital lesions responding best, followed by the scalp and then the palms and soles. He positioned icotrokinra as an option for patients preferring an oral treatment, while steering those prioritizing maximum efficacy toward top-performing biologics.

Advances in Treating High-Impact Psoriasis From EADV 2026

Christopher G. Bunick, MD, PhD, of Yale School of Medicine, discussed 52-week results from the phase 4 UnlIMMited trial of risankizumab in genital and scalp psoriasis. In the genital psoriasis study, 81.5% of patients continuing risankizumab achieved clear or almost clear genital skin at Week 52, and 80.5% reported meaningful improvement in genital itch. Bunick emphasized the substantial effect of genital psoriasis on sexual health and identified treatment sequencing in biologic-experienced patients as a key research gap.

Stay tuned to HCPLive for continued dermatology coverage from recent meetings.